AU734220B2 - Cloning and characterization of napsin, an aspartic protease - Google Patents
Cloning and characterization of napsin, an aspartic protease Download PDFInfo
- Publication number
- AU734220B2 AU734220B2 AU54592/98A AU5459298A AU734220B2 AU 734220 B2 AU734220 B2 AU 734220B2 AU 54592/98 A AU54592/98 A AU 54592/98A AU 5459298 A AU5459298 A AU 5459298A AU 734220 B2 AU734220 B2 AU 734220B2
- Authority
- AU
- Australia
- Prior art keywords
- napsin
- human
- seq
- enzyme
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 102000035101 Aspartic proteases Human genes 0.000 title claims abstract description 39
- 108091005502 Aspartic proteases Proteins 0.000 title claims abstract description 39
- 238000010367 cloning Methods 0.000 title description 6
- 238000012512 characterization method Methods 0.000 title description 3
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 40
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 24
- 239000002773 nucleotide Substances 0.000 claims abstract description 22
- 125000003729 nucleotide group Chemical group 0.000 claims abstract description 22
- 235000018102 proteins Nutrition 0.000 claims description 22
- 150000001413 amino acids Chemical class 0.000 claims description 15
- 108010029485 Protein Isoforms Proteins 0.000 claims description 7
- 102000001708 Protein Isoforms Human genes 0.000 claims description 7
- 210000004899 c-terminal region Anatomy 0.000 claims description 6
- 235000001014 amino acid Nutrition 0.000 claims description 5
- 238000011160 research Methods 0.000 claims description 4
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- 125000000539 amino acid group Chemical group 0.000 claims 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 claims 1
- VYXXMAGSIYIYGD-NWAYQTQBSA-N propan-2-yl 2-[[[(2R)-1-(6-aminopurin-9-yl)propan-2-yl]oxymethyl-(pyrimidine-4-carbonylamino)phosphoryl]amino]-2-methylpropanoate Chemical compound CC(C)OC(=O)C(C)(C)NP(=O)(CO[C@H](C)Cn1cnc2c(N)ncnc12)NC(=O)c1ccncn1 VYXXMAGSIYIYGD-NWAYQTQBSA-N 0.000 claims 1
- 239000002299 complementary DNA Substances 0.000 abstract description 27
- 102000004190 Enzymes Human genes 0.000 abstract description 26
- 108090000790 Enzymes Proteins 0.000 abstract description 26
- 238000000034 method Methods 0.000 abstract description 20
- 210000001519 tissue Anatomy 0.000 abstract description 14
- 108090000258 Cathepsin D Proteins 0.000 abstract description 13
- 238000001514 detection method Methods 0.000 abstract description 13
- 102000003908 Cathepsin D Human genes 0.000 abstract description 12
- 239000000523 sample Substances 0.000 abstract description 12
- 108091005804 Peptidases Proteins 0.000 abstract description 9
- 239000004365 Protease Substances 0.000 abstract description 9
- 210000004185 liver Anatomy 0.000 abstract description 8
- 238000002955 isolation Methods 0.000 abstract description 6
- 230000008569 process Effects 0.000 abstract description 5
- 238000003556 assay Methods 0.000 abstract description 4
- 238000003776 cleavage reaction Methods 0.000 abstract description 4
- 230000007017 scission Effects 0.000 abstract description 4
- 108010044467 Isoenzymes Proteins 0.000 abstract description 2
- 230000007062 hydrolysis Effects 0.000 abstract description 2
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 2
- 238000000746 purification Methods 0.000 abstract description 2
- 210000005084 renal tissue Anatomy 0.000 abstract description 2
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 2
- 229940088598 enzyme Drugs 0.000 description 21
- 241001465754 Metazoa Species 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 12
- 108020004414 DNA Proteins 0.000 description 10
- 108020004705 Codon Proteins 0.000 description 9
- 101000581940 Homo sapiens Napsin-A Proteins 0.000 description 8
- BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 8
- 229910052921 ammonium sulfate Inorganic materials 0.000 description 8
- 235000011130 ammonium sulphate Nutrition 0.000 description 8
- 239000000872 buffer Substances 0.000 description 8
- 238000009396 hybridization Methods 0.000 description 8
- 238000012216 screening Methods 0.000 description 8
- 102000035195 Peptidases Human genes 0.000 description 7
- 102000046387 human NAPSA Human genes 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- 238000003752 polymerase chain reaction Methods 0.000 description 7
- 108091028043 Nucleic acid sequence Proteins 0.000 description 6
- 102000057297 Pepsin A Human genes 0.000 description 6
- 108090000284 Pepsin A Proteins 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 108010062466 Enzyme Precursors Proteins 0.000 description 5
- 102000010911 Enzyme Precursors Human genes 0.000 description 5
- 108091034117 Oligonucleotide Proteins 0.000 description 5
- 229940111202 pepsin Drugs 0.000 description 5
- 241000894007 species Species 0.000 description 5
- 206010006187 Breast cancer Diseases 0.000 description 4
- 208000026310 Breast neoplasm Diseases 0.000 description 4
- 108090000783 Renin Proteins 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 208000035475 disorder Diseases 0.000 description 4
- 102000006495 integrins Human genes 0.000 description 4
- 239000012528 membrane Substances 0.000 description 4
- 108020004999 messenger RNA Proteins 0.000 description 4
- 239000013615 primer Substances 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 229920000936 Agarose Polymers 0.000 description 3
- 108700024394 Exon Proteins 0.000 description 3
- 102000055441 Gastricsin Human genes 0.000 description 3
- 108090001072 Gastricsin Proteins 0.000 description 3
- 206010020772 Hypertension Diseases 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 102100028255 Renin Human genes 0.000 description 3
- 239000007983 Tris buffer Substances 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 210000004408 hybridoma Anatomy 0.000 description 3
- 108010044426 integrins Proteins 0.000 description 3
- IZWSFJTYBVKZNK-UHFFFAOYSA-N lauryl sulfobetaine Chemical compound CCCCCCCCCCCC[N+](C)(C)CCCS([O-])(=O)=O IZWSFJTYBVKZNK-UHFFFAOYSA-N 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 229950000964 pepstatin Drugs 0.000 description 3
- 108010091212 pepstatin Proteins 0.000 description 3
- FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 3
- 108010028067 procathepsin D Proteins 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 3
- HKJKONMZMPUGHJ-UHFFFAOYSA-N 4-amino-5-hydroxy-3-[(4-nitrophenyl)diazenyl]-6-phenyldiazenylnaphthalene-2,7-disulfonic acid Chemical compound OS(=O)(=O)C1=CC2=CC(S(O)(=O)=O)=C(N=NC=3C=CC=CC=3)C(O)=C2C(N)=C1N=NC1=CC=C([N+]([O-])=O)C=C1 HKJKONMZMPUGHJ-UHFFFAOYSA-N 0.000 description 2
- 101150076489 B gene Proteins 0.000 description 2
- 108090000994 Catalytic RNA Proteins 0.000 description 2
- 102000053642 Catalytic RNA Human genes 0.000 description 2
- 102000004178 Cathepsin E Human genes 0.000 description 2
- 108090000611 Cathepsin E Proteins 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000869010 Homo sapiens Cathepsin D Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- 239000002033 PVDF binder Substances 0.000 description 2
- 108010076504 Protein Sorting Signals Proteins 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 239000007997 Tricine buffer Substances 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000003197 catalytic effect Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000002596 correlated effect Effects 0.000 description 2
- 230000000875 corresponding effect Effects 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 102000053356 human CTSD Human genes 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 230000000984 immunochemical effect Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 210000003292 kidney cell Anatomy 0.000 description 2
- 210000000231 kidney cortex Anatomy 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 235000018977 lysine Nutrition 0.000 description 2
- 125000003588 lysine group Chemical class [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 108091092562 ribozyme Proteins 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 239000013598 vector Substances 0.000 description 2
- FJQZXCPWAGYPSD-UHFFFAOYSA-N 1,3,4,6-tetrachloro-3a,6a-diphenylimidazo[4,5-d]imidazole-2,5-dione Chemical compound ClN1C(=O)N(Cl)C2(C=3C=CC=CC=3)N(Cl)C(=O)N(Cl)C12C1=CC=CC=C1 FJQZXCPWAGYPSD-UHFFFAOYSA-N 0.000 description 1
- CFBILACNYSPRPM-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;2-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]amino]acetic acid Chemical compound OCC(N)(CO)CO.OCC(CO)(CO)NCC(O)=O CFBILACNYSPRPM-UHFFFAOYSA-N 0.000 description 1
- 102000015427 Angiotensins Human genes 0.000 description 1
- 108010064733 Angiotensins Proteins 0.000 description 1
- 101100289888 Caenorhabditis elegans lys-5 gene Proteins 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 239000003155 DNA primer Substances 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- 108091036060 Linker DNA Proteins 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 101100166423 Mus musculus Ccdc47 gene Proteins 0.000 description 1
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
- 102100027343 Napsin-A Human genes 0.000 description 1
- 108700026244 Open Reading Frames Proteins 0.000 description 1
- 108010047320 Pepsinogen A Proteins 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 108020004511 Recombinant DNA Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 108091081024 Start codon Proteins 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 238000000246 agarose gel electrophoresis Methods 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 210000004436 artificial bacterial chromosome Anatomy 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 150000001510 aspartic acids Chemical class 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000012631 diagnostic technique Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 230000016784 immunoglobulin production Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000005304 joining Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000006249 magnetic particle Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- YFCUZWYIPBUQBD-ZOWNYOTGSA-N n-[(3s)-7-amino-1-chloro-2-oxoheptan-3-yl]-4-methylbenzenesulfonamide;hydron;chloride Chemical compound Cl.CC1=CC=C(S(=O)(=O)N[C@@H](CCCCN)C(=O)CCl)C=C1 YFCUZWYIPBUQBD-ZOWNYOTGSA-N 0.000 description 1
- 150000007523 nucleic acids Chemical group 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000002987 primer (paints) Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000004393 prognosis Methods 0.000 description 1
- 108010008380 pronapsin Proteins 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000004153 renaturation Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000011282 treatment Methods 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 241001515965 unidentified phage Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6478—Aspartic endopeptidases (3.4.23)
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3119696P | 1996-11-20 | 1996-11-20 | |
| US60/031196 | 1996-11-20 | ||
| US4612697P | 1997-05-09 | 1997-05-09 | |
| US60/046126 | 1997-05-09 | ||
| PCT/US1997/021684 WO1998022597A2 (en) | 1996-11-20 | 1997-11-20 | Cloning and characterization of napsin, an aspartic protease |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU5459298A AU5459298A (en) | 1998-06-10 |
| AU734220B2 true AU734220B2 (en) | 2001-06-07 |
Family
ID=26706937
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU54592/98A Ceased AU734220B2 (en) | 1996-11-20 | 1997-11-20 | Cloning and characterization of napsin, an aspartic protease |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US6225103B1 (enExample) |
| EP (1) | EP0948630B1 (enExample) |
| JP (2) | JP2001503643A (enExample) |
| AT (1) | ATE393227T1 (enExample) |
| AU (1) | AU734220B2 (enExample) |
| CA (1) | CA2271294A1 (enExample) |
| DE (1) | DE69738653T2 (enExample) |
| DK (1) | DK0948630T3 (enExample) |
| ES (1) | ES2308791T3 (enExample) |
| PT (1) | PT948630E (enExample) |
| WO (1) | WO1998022597A2 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0897986A3 (en) * | 1997-08-21 | 2000-07-05 | Smithkline Beecham Corporation | Aspartic proteinase 5 (ASP5) |
| US6203979B1 (en) | 1998-01-16 | 2001-03-20 | Incyte Pharmaceuticals, Inc. | Human protease molecules |
| US7045333B1 (en) * | 1998-01-16 | 2006-05-16 | Incyte Corporation | Human protease molecules |
| US6432690B1 (en) * | 1998-01-16 | 2002-08-13 | Incyte Genomics, Inc. | Human aspartic proteases |
| US7160679B1 (en) | 1998-05-21 | 2007-01-09 | Diadexus, Inc. | Method of diagnosing, monitoring, and staging lung cancer |
| CA2303062A1 (en) * | 1998-07-16 | 2000-01-27 | Incyte Pharmaceuticals, Inc. | Human aspartic proteases |
| EP1939297A1 (en) | 1998-09-24 | 2008-07-02 | Pharmacia & Upjohn Company LLC | Alzheimer's disease secretase |
| US7456007B1 (en) | 1998-12-31 | 2008-11-25 | Elan Pharmaceuticals, Inc. | β-secretase enzyme compositions and methods |
| US7115410B1 (en) | 1999-02-10 | 2006-10-03 | Elan Pharmaceuticals, Inc. | β-secretase enzyme compositions and methods |
| NZ534876A (en) | 1999-02-10 | 2006-02-24 | Elan Pharm Inc | Human beta-secretase enzyme, inhibitors and their compositions and uses |
| US7514408B1 (en) | 1999-12-02 | 2009-04-07 | Elan Pharmaceuticals, Inc. | β-secretase enzyme compositions and methods |
| JP2001172200A (ja) * | 1999-12-17 | 2001-06-26 | Meneki Seibutsu Kenkyusho:Kk | ヒトナプシンａに対する抗体およびこれを用いる医薬 |
| ES2275675T3 (es) | 2000-03-23 | 2007-06-16 | Elan Pharmaceuticals, Inc. | Compuestos y metodos para tratar la enfermedad de alzheimer. |
| WO2002000891A2 (en) * | 2000-06-26 | 2002-01-03 | Bayer Aktiengesellschaft | Human napsin-like aspartyl protease |
| EP1666452A2 (en) | 2000-06-30 | 2006-06-07 | Elan Pharmaceuticals, Inc. | Compounds to treat Alzheimer's disease |
| PE20020276A1 (es) | 2000-06-30 | 2002-04-06 | Elan Pharm Inc | COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER |
| ES2252257T3 (es) | 2000-06-30 | 2006-05-16 | Elan Pharmaceuticals, Inc. | Compuestos para tratar la enfermedad de alzheimer. |
| US6846813B2 (en) | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
| EP1500663A1 (en) * | 2000-09-28 | 2005-01-26 | Eli Lilly And Company | Secreted proteins and their uses |
| US7217556B1 (en) | 2000-12-23 | 2007-05-15 | Pfizer Inc | Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in Alzheimer's disease |
| US7601528B1 (en) | 2000-12-23 | 2009-10-13 | Elan Pharmaceuticals, Inc. | Crystallization and structure determination of glycosylated human beta secretase, an enzyme implicated in alzheimer's disease |
| US7806980B2 (en) * | 2000-12-23 | 2010-10-05 | Elan Pharmaceuticals, Inc. | Method for crystallizing human beta secretase in complex with an inhibitor |
| US7524668B1 (en) * | 2001-05-10 | 2009-04-28 | Elan Pharmaceuticals, Inc. | Crystal of human beta secretase having monoclinic space group symmetry C2 and methods for crystallization thereof |
| US7384773B1 (en) | 2001-05-10 | 2008-06-10 | Pfizer Inc | Crystal of HIV protease-cleaved human beta secretase and method for crystallization thereof |
| CA2448834A1 (en) | 2001-06-01 | 2002-12-12 | Elan Pharmaceuticals, Inc. | Hydroxy alkyl amine derivatives as beta-secretase inhibitors and their use for the treatment of alzheimer's disease and similar diseases |
| CA2450205A1 (en) | 2001-06-13 | 2002-12-19 | Elan Pharmaceuticals, Inc. | Aminediols for the treatment of alzheimer's disease |
| CA2452039A1 (en) | 2001-06-27 | 2003-01-09 | Elan Pharmaceuticals, Inc. | Beta-hydroxyamine derivatives useful in treatment of alzheimer's disease |
| CA2453451A1 (en) | 2001-07-10 | 2003-01-23 | Elan Pharmaceuticals, Inc. | Aminediols for the treatment of alzheimer's disease |
| WO2003006013A1 (en) | 2001-07-10 | 2003-01-23 | Elan Pharmaceuticals, Inc. | Diaminediols for the treatment of alzheimer's disease |
| US7186539B1 (en) | 2001-08-31 | 2007-03-06 | Pharmacia & Upjohn Company | Method for refolding enzymes |
| CA2462851A1 (en) | 2001-10-04 | 2003-04-10 | Elan Pharmaceuticals, Inc. | Hydroxypropylamines |
| AR039555A1 (es) | 2001-11-08 | 2005-02-23 | Upjohn Co | Derivados n,n'-sustituidos de 1,3-diamino-2-hidroxipropano |
| CA2477243A1 (en) | 2002-02-21 | 2003-09-04 | Pharmacia & Upjohn Company | Modified bace |
| WO2004058686A1 (en) | 2002-04-30 | 2004-07-15 | Elan Pharmaceuticals, Inc. | Hydroxypropyl amides for the treatment of alzheimer’s disease |
| US7442537B1 (en) | 2002-05-10 | 2008-10-28 | Elan Pharmaceuticals, Inc. | Crystals of unliganded beta secretase and/or beta secretase-like proteins and the use thereof |
| WO2004009797A2 (en) * | 2002-07-23 | 2004-01-29 | Incyte Corporation | Protein modification and maintenance molecules |
| BR0316629A (pt) | 2002-11-27 | 2005-10-11 | Elan Pharm Inc | Uréias e carbamatos substituìdos |
| TW200512195A (en) | 2003-04-21 | 2005-04-01 | Elan Pharm Inc | Benzamide 2-hydroxy-3-diaminoalkanes |
| JP4739192B2 (ja) | 2003-05-02 | 2011-08-03 | イーラン ファーマスーティカルズ、インコーポレイテッド | Ｂａｃｅのグリコシル化変異体 |
| WO2005044977A2 (en) * | 2003-06-25 | 2005-05-19 | Diadexus, Inc. | Compositions, splice variants and methods relating to lung specific genes and proteins |
| JP2007528400A (ja) | 2004-03-09 | 2007-10-11 | エラン ファーマシューティカルズ，インコーポレイテッド | 置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬 |
| WO2005095454A1 (en) * | 2004-03-25 | 2005-10-13 | Diadexus, Inc. | Lng105 antibody composition and methods of use, and use of lng105 to assess lung cancer risk |
| JP2008505930A (ja) | 2004-07-09 | 2008-02-28 | エラン ファーマシューティカルズ，インコーポレイテッド | オキシム誘導体置換ヒドロキシエチルアミン系のアスパラギン酸プロテアーゼ阻害薬 |
| WO2007047305A1 (en) | 2005-10-12 | 2007-04-26 | Elan Pharmaceuticals, Inc. | Methods of treating amyloidosis using cyclopropyl derivative aspartyl protease inhibitors |
| CA2687750C (en) | 2007-07-06 | 2016-10-18 | Boehringer Ingelheim International Gmbh | Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL107250A (en) * | 1993-10-12 | 2001-08-08 | Yeda Res & Dev | Dna molecules involved in programmed cell death, proteins encoded thereby and methods and compositions using said dna molecules and proteins |
| GB9618966D0 (en) * | 1996-09-11 | 1996-10-23 | Smithkline Beecham Plc | Novel compounds |
| US5776759A (en) * | 1996-09-26 | 1998-07-07 | Incyte Pharmaceuticals, Inc. | Two novel human cathepsin proteins |
-
1997
- 1997-11-20 WO PCT/US1997/021684 patent/WO1998022597A2/en not_active Ceased
- 1997-11-20 DK DK97948546T patent/DK0948630T3/da active
- 1997-11-20 ES ES97948546T patent/ES2308791T3/es not_active Expired - Lifetime
- 1997-11-20 AU AU54592/98A patent/AU734220B2/en not_active Ceased
- 1997-11-20 AT AT97948546T patent/ATE393227T1/de active
- 1997-11-20 PT PT97948546T patent/PT948630E/pt unknown
- 1997-11-20 US US08/974,691 patent/US6225103B1/en not_active Expired - Lifetime
- 1997-11-20 JP JP52398598A patent/JP2001503643A/ja not_active Withdrawn
- 1997-11-20 CA CA002271294A patent/CA2271294A1/en not_active Abandoned
- 1997-11-20 EP EP97948546A patent/EP0948630B1/en not_active Expired - Lifetime
- 1997-11-20 DE DE69738653T patent/DE69738653T2/de not_active Expired - Lifetime
-
2007
- 2007-11-15 JP JP2007297327A patent/JP2008118996A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| WO1998022597A3 (en) | 1998-07-09 |
| WO1998022597A2 (en) | 1998-05-28 |
| JP2008118996A (ja) | 2008-05-29 |
| DE69738653D1 (de) | 2008-06-05 |
| ES2308791T3 (es) | 2008-12-01 |
| EP0948630B1 (en) | 2008-04-23 |
| DK0948630T3 (da) | 2008-08-11 |
| AU5459298A (en) | 1998-06-10 |
| CA2271294A1 (en) | 1998-05-28 |
| US6225103B1 (en) | 2001-05-01 |
| DE69738653T2 (de) | 2009-06-04 |
| PT948630E (pt) | 2008-06-11 |
| JP2001503643A (ja) | 2001-03-21 |
| ATE393227T1 (de) | 2008-05-15 |
| EP0948630A2 (en) | 1999-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU734220B2 (en) | Cloning and characterization of napsin, an aspartic protease | |
| WO1998022597A9 (en) | Cloning and characterization of napsin, an aspartic protease | |
| AU699748B2 (en) | Recombinant HK2 polypeptide | |
| WO1995030758A9 (en) | Recombinant hk2 polypeptide | |
| US6191255B1 (en) | Protein and monoclonal antibody specific thereto | |
| CN102430117A (zh) | 抑制补体激活的修饰的蛋白酶 | |
| SK288119B6 (sk) | Von Willebrand Factor (vWF) cleaving protease polypeptide, nucleic acid encoding the polypeptide and use of polypeptide | |
| JP4205738B2 (ja) | 安定ｈｋ２ポリペプチド変異体 | |
| JPH07303482A (ja) | 新規なメタロプロテアーゼおよびそれをコードするｄｎａ | |
| JPS62111690A (ja) | ヒト―プロテインｃをコードする遺伝子 | |
| AU2003207795B2 (en) | Aggrecanase molecules | |
| CA2217492A1 (en) | Amyloid precursor protein protease | |
| AU737659B2 (en) | Method for detection of metastatic prostate cancer | |
| JP3955636B2 (ja) | Ｈｋ２ポリペプチドを検出するための方法 | |
| JPH09235300A (ja) | ヒトｔｉｍｐ−３及び抗ヒトｔｉｍｐ−３モノクローナル抗体並びにその用途 | |
| WO1998002748A9 (en) | Methods to detect hk2 polypeptides | |
| JPH07203961A (ja) | 新規なメタロプロテアーゼおよびそれをコードするｄｎａ | |
| MXPA96005473A (en) | Polipeptido hk2 recombina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) |